First Capital Advisors Group’s Regeneron Pharmaceuticals REGN Stock Holding History

First Capital Advisors Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$6.47K	Buy	+9	New	+$6.94K	﹤0.01%	623
2018 Q2	–	Sell	-15	Closed	-$5K	–	631
2018 Q1	$5K	Buy	+15	New	+$5.22K	﹤0.01%	643

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Capital Advisors Group's REGN Position: Q2 2023 in Review

First Capital Advisors Group opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2023: 9 shares worth $6.47K. The stake represents ﹤0.01% of the portfolio and ranks #623 among its holdings. This is a return to the name: First Capital Advisors Group previously reported a position in REGN as recently as Q1 2018.

First Capital Advisors Group first reported a position in REGN in Q1 2018 and has held it in 2 quarters since. 1,165 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

First Capital Advisors Group held 9 shares of Regeneron Pharmaceuticals worth $6.47K as of Q2 2023.
Regeneron Pharmaceuticals was a new First Capital Advisors Group position in Q2 2023.
Regeneron Pharmaceuticals made up ﹤0.01% of First Capital Advisors Group's portfolio in Q2 2023, its #623 holding.
First Capital Advisors Group first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 2 quarters since.
1,165 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on First Capital Advisors Group's 13F filing for Q2 2023, filed 15 Aug 2023.